EU MDR Readiness: Why Companies Still Struggle

What does “EU MDR readiness” mean in practice?

EU MDR readiness means ensuring that your submission documentation tells a connected story about how data directly supports your intended use statement, which is tied to product design, risk files, clinical data, labeling, and your post-market surveillance (PMS) plan.

A small-to-mid-sized medical device manufacturer spent two years preparing its EU MDR submission in accordance with the outline provided by its notified body. The verification reports were complete. The Clinical Evaluation Report (CER) was over 400 pages and included 100 literature references. The risk management file looked elegant.

Then the team was asked one simple question:

“Please show how your product-specific risk documentation is linked to your validation evidence and reflected in the IFU.” The room went silent.

The evidence existed, but it was spread across documents written by different teams. The cross-functional review did not catch it. It was not the absence of data that delayed certification. It was the absence of traceability. The medical writer reviewed 100 literature references but failed to differentiate between those using the medical device “as intended” and those using it “off-label.” No action was taken to determine whether the risk management file or labeling needed to be updated.

Is there a document I can use to guide my EU MDR submission?

Yes. That is exactly the problem the updated TEAM-NB Technical Documentation guidance is trying to solve. TEAM-NB recently published a 2026 revision of its “Team-NB Position Paper” on Technical Documentation, “MDR / IVDR Revision: Impact on the Sector.”

https://www.team-nb.org/team-nb-documents/

Do you want your EU MDR submission team to be ready? Have your team read this. The updated position paper represents one of the clearest signals yet that notified bodies are moving toward a far more structured, evidence-linked, and lifecycle-based assessment model for medical devices.

TEAM-NB clearly positions technical documentation as a “living system” tied directly to design changes, supplier controls, manufacturing validation, complaint handling, PMS activities, and PMCF outputs.

Key components include:

1. Structured and connected technical documentation
2. Clear alignment among risk management, clinical evaluation, verification and validation, labeling, and post-market surveillance
3. Clinical evaluation supported by sufficient and appropriate data
4. Connected evidence across the entire quality and regulatory framework
5. Planned and active post-market surveillance (PMS) and post-market clinical follow-up (PMCF)

What are notified bodies looking for in your EU MDR submissions?

Notified bodies are increasingly focused on traceability and lifecycle integration.

They will ask:

1. Does the risk file reflect clinical outcomes and current data?
2. Are complaints linked to benefit-risk decisions?
3. Is PMS actively driving changes to the product and documentation?
4. Can you show an example of how publicly available information feeds back into device design, risk management, and labeling?

Readiness is not a one-time milestone achieved before submission. It must be maintained continuously as new clinical data, including complaints, medical literature, clinical trials, and field data, are added to the organization.

A lack of testing, clinical data, or procedures should not cause silence in that room next time. Why? Because the silence came from a deeper issue that many manufacturers are still struggling with under the EU MDR: the inability to clearly connect the entire regulatory story of the device.

In many ways, the manufacturers that will succeed under the EU MDR will not necessarily be those with the largest number of documents. They will be the organizations capable of demonstrating clarity, consistency, traceability, and alignment across the entire technical documentation structure. There will not be silence next time.

To go deeper, SGS offers EU MDR training programs focused on technical documentation, audit readiness, regulatory expectations, and practical implementation strategies.